Pharmaceuticals APAC

APAC Gene Therapy for Hemophilia Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $90.9 Mn Placeholder estimate
Estimate 2025 $119.5 Mn 23.6% of the global market
Projected 2034 $1.40 Bn 1,075.8% Adds $1.29 Bn over 9 forecast years
CAGR 2025–2034 31.5% Faster than 97% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 23.57% of the global market.
  • Among regions, the largest is North America at $257.1 Mn.
  • Fastest growing: Africa at 31.8% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.29 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Gene Therapy for Hemophilia Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $90.9 Mn — —
2025 (base) $119.5 Mn +$28.6 Mn —
2026 (forecast) $157.1 Mn +$37.6 Mn +31.5%
2027 (forecast) $206.6 Mn +$49.5 Mn +72.9%
2028 (forecast) $271.7 Mn +$65.1 Mn +127.4%
2029 (forecast) $357.3 Mn +$85.6 Mn +199%
2030 (forecast) $469.8 Mn +$112.5 Mn +293.2%
2031 (forecast) $617.9 Mn +$148.0 Mn +417.1%
2032 (forecast) $812.5 Mn +$194.6 Mn +580%
2033 (forecast) $1.07 Bn +$255.9 Mn +794.1%
2034 (forecast) $1.40 Bn +$336.5 Mn +1,075.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Gene Therapy for Hemophilia Market Analysis at a glance
Market size, 2025$119.5 Mn placeholder estimate
Forecast, 2034$1.40 Bn placeholder estimate
Growth (CAGR), 2025–203431.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, vector and end user (see all)
Key playersBioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all)
Active clinical trials15 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Gene Therapy for Hemophilia Market Analysis Executive Summary

Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.

Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).

Bar chart: Asia Pacific Gene Therapy for Hemophilia market size, 2024–2034, placeholder estimates. $90.9 Mn in 2024, $119.5 Mn in 2025 and $1.40 Bn in 2034, 31.5% CAGR.
Asia Pacific Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Gene Therapy for Hemophilia Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Gene Therapy for Hemophilia Market in APAC

The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in APAC

Gene Therapy for Hemophilia in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 15 studies on Gene Therapy for Hemophilia that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.

Clinical trials

15 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanghai Xinzhi BioMed Co., Ltd. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gene Therapy for Hemophilia in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Gene Therapy for Hemophilia market in Asia Pacific?
Placeholder estimate: about $119.5 Mn in 2025, rising to about $1.40 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in Asia Pacific growing?
Placeholder estimate: about 31.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
How many clinical trials on Gene Therapy for Hemophilia are running in Asia Pacific?
15 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on cell and gene therapy and rare diseases

See the topic